Understanding Active Surveillance In Favorable Intermediate Risk Prostate Cancer
Welcome to our comprehensive guide on Active Surveillance In Favorable Intermediate Risk Prostate Cancer. James A. Eastham, MD, FACS, considers how to select candidates for
Key Takeaways about Active Surveillance In Favorable Intermediate Risk Prostate Cancer
- In this inaugural episode of The UroOnc Minute from Urology Times, host Adam Weiner, MD, sits down with Michael S. Leapman, ...
- James A. Eastham, MD, FACS explores
- If you have low
- Kevin Ginsburg, MD, urologic oncologist at the Karmanos
- Mark Scholz, MD (oncologist), explains that Gleason 7,
Detailed Analysis of Active Surveillance In Favorable Intermediate Risk Prostate Cancer
When is Active Surveillance Patients with Gleason 3+4=7 represent one of the largest "grey areas" in the world of
Learn more about Dr. Matthew Cooperberg here: https://urology.ucsf.edu/people/cooperberg To learn more about
In summary, understanding Active Surveillance In Favorable Intermediate Risk Prostate Cancer gives us a better perspective.
